



Perma-Fix Medical Provides Business Update

Schedules Investor Webcast for August 25th at 2:00 PM Central European Time

Warsaw and Atlanta – August 25, 2015 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today provided a general business update. The Company also announced it will host a business update call at 2:00 PM Central European time (8:00 a.m. Eastern time) on Tuesday, August 25, 2015, via webcast on the company's website: www.medical-isotope.com.

Steve Belcher, Chief Executive Officer of Perma-Fix Medical S.A. stated, "We are pleased to report a number of important developments during the quarter. First, we successfully scaled up our prototype generator for commercial production of Technetium-99m (Tc-99m) by achieving production at the 4 curie level, which marks a major achievement within the industry. We not only exceeded industry requirements in many emerging markets that are in need of a decentralized and stable supply chain, but we are also moving rapidly to demonstrate our superiority over traditional processes in the North American and European markets. Based on these results, we remain convinced that our process has the potential to reshape the global supply chain of Tc-99m in the United States and around the world."

"Following our earlier success at the 2 curie level, we have attracted significant interest from within the industry—further validating the significance of our process. Given our latest success at the 4 curie level, and near term plans to scale up even further, we are moving forward aggressively with our plans to formalize additional partnerships, prepare for regulatory submission, and, ultimately, commence commercialization of the process."

"We also finalized our agreement with Digirad Corporation, whereby Digirad invested \$1 million into the company. The fact that they invested at a significant premium to the market price is further illustration of the growing interest in our process from within the industry. As part of the agreement, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations upon successful completion of development of the new Tc-99m resin."

Dr. Louis F. Centofanti, Chairman, stated, "Given our rapid progress, we made some important additions to the senior management team. We are pleased to welcome Steve Belcher who has been appointed Chief Executive Officer of Perma-Fix Medical. Steve brings over 20 years of experience in the nuclear pharmaceutical sector and was a founder, principal, and former Vice President of Triad Isotopes, which was formed in 2007 and has grown to 60 pharmacies and \$270 million in sales. We are also pleased to welcome John Climaco, who was appointed Executive Vice President of Perma-Fix Medical. He brings over a decade of experience in the diagnostics industry. He is a cofounder and former President and Chief Executive Officer of Axial Biotech, Inc., a molecular diagnostics company and serves as a Member of the Board of Directors for Perma-Fix Environmental Services, Digirad Corporation and InfuSystem Holdings, all NASDAQ listed companies."

Dr. Centofanti concluded, "Having validated our technology at two leading nuclear institutions, we are presently scaling up the process at higher curie levels and will disclose more on this front in the very near future. As a next step, we are also focused on establishing strategic partnerships with additional companies involved in the Tc-99m supply chain. We believe our innovative process of Tc-99m production will be extremely well received in both North America and Europe as it addresses the global need for a safer, more reliable, more cost-effective and uranium-free solution to Tech-99m production."

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszwaska or David K. Waldman
Crescendo Communications Europe Sp. z.o.o
Tel: (+48 71) 79 11 551
Email : pfm@crescendo-ir.com